


# Combining oncolytic vaccine therapy with adoptive cell therapy to target cancers expressing MAGE-A3

July 1, 2015 to June 30, 2017

## Highlights

- Enables application for a world-first clinical trial combining adoptive cell therapy with the internationally recognized Canadian innovation of oncolytic vaccines.
- Prepares an exciting combination of technologies that have a clear mechanism for working together to kill cancer cells.



# Enabling Study investigators



**BioCanRx**  
**\$263,181**  
approved on  
June 10, 2015

## BioCanRx core facilities

GMP viral vector laboratory  
McMaster University

GMP viral vector laboratory  
The Ottawa Hospital

GMP cell therapy lab  
Hôpital Maisonneuve-Rosemont

**July 1, 2015**  
• Project starts

- Collect T cells from three patients
- Arrange and hold pre-CTA (Clinical Trial Application) meeting with Health Canada

- Collect T cells from three more patients
- Complete testing of three samples in mice with immune systems that mimic the human immune system

- Complete testing of additional three samples in mice with immune systems that mimic the human immune system
- Analyze and prepare data to support writing and submission of CTA for Health Canada submission

**The power to kill cancer lies within us.  
Let's tell our bodies how.**

